Pablo Bagnati

ORCID: 0000-0003-2801-0537
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Dementia and Cognitive Impairment Research
  • Health Systems, Economic Evaluations, Quality of Life
  • Alzheimer's disease research and treatments
  • Genomics and Rare Diseases
  • Functional Brain Connectivity Studies
  • Neurotransmitter Receptor Influence on Behavior
  • Attention Deficit Hyperactivity Disorder
  • Treatment of Major Depression
  • Aging, Elder Care, and Social Issues
  • Aging, Health, and Disability
  • Amyotrophic Lateral Sclerosis Research
  • Health and Medical Education
  • Health, Environment, Cognitive Aging
  • BRCA gene mutations in cancer
  • Child Nutrition and Feeding Issues
  • Advanced Neuroimaging Techniques and Applications
  • Educational Outcomes and Influences
  • Psychology Research and Bibliometrics
  • Mental Health and Psychiatry
  • Medical research and treatments
  • Health, Medicine and Society
  • Transcranial Magnetic Stimulation Studies
  • Technology Use by Older Adults
  • Psychosomatic Disorders and Their Treatments
  • Cardiac Health and Mental Health

Instituto de Neurología Cognitiva
2013-2025

Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia
2013-2024

The Memory Clinic
2021

California Retina Consultants
2010

Abstract INTRODUCTION This study involved evaluating a tailored genetic counseling and testing (GCT) protocol for families at risk of autosomal dominant Alzheimer's disease (ADAD) in Latin America (LatAm), focusing on essential cultural regional adaptations. METHODS We conducted non‐randomized controlled trial among ADAD Colombia Argentina. Participants were categorized based their decision to learn status (GS), with further comparisons between mutation‐positive versus mutation‐negative...

10.1002/dad2.70102 article EN cc-by-nc-nd Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring 2025-04-01

Abstract INTRODUCTION Imaging biomarkers are fundamental in diagnosing neurodegenerative diseases, but their use FTD remains limited. This study examines PET Argentine bvFTD patients. METHODS We studied a cohort of patients ( n = 20) and controls 21) with three different radiotracers (18F‐FDG, 11C‐PiB, 18F‐AV1451). RESULTS In patients, 18F‐FDG showed significant hypometabolism frontotemporal regions, along hypermetabolism the precentral gyrus, compared to normal controls. 11C‐PIB did not...

10.1002/alz.70187 article EN cc-by-nc Alzheimer s & Dementia 2025-04-01

ABSTRACT There is evidence for an association between vascular disease and depression, in particular cerebrovascular especially that occurring later life. Among the diverse psychiatric diseases, one which most widely studied concerning relationship with system, depression. The risk depression events a two-way road: presence of increases cardiovascular event (worsening its evolution prognosis, as well) patient evidencing or heart disease, will also show increase suffering (Taragano et al. ,...

10.1017/s1748232106000103 article EN Progress in Neurotherapeutics and Neuropsychopharmacology 2006-07-21

Abstract Background Frontotemporal dementia (FTD) remains one of the most common forms early‐onset (45 to 65 years). FTD consists clinically and pathologically a heterogeneous group disorders characterized by progressive frontal temporal lobe atrophy. Thirty fifty percent cases have family history disease. In this work we aimed characterize pathogenic variants implicated in familial cohort from Argentina. Method A total 43 patients (23 women, 20 men) meeting clinical criteria for probable...

10.1002/alz.085944 article EN cc-by Alzheimer s & Dementia 2024-12-01

Abstract Background Genetic testing for individuals with dominantly inherited Alzheimer’s disease (DIAD) is now of greater relevance due to the existence therapeutic trials available this population. However, impact and main drivers influencing decision seek genetic are relatively unknown in Latin America (LatAm). Here we present results from a regional counseling protocol implemented LatAm. Method Our aim was investigate psychosocial asymptomatic families DIAD. A non‐randomized, controlled,...

10.1002/alz.084526 article EN cc-by Alzheimer s & Dementia 2024-12-01

Frontotemporal dementia (FTD) is a neurodegenerative disease and one of the most common causes in people under 65. There often significant diagnostic delay, as FTD can be confused with other psychiatric conditions. A lack knowledge regarding by health professionals possible cause for this confusion.The aim study was to adapt validate Dementia Knowledge Scale (FTDKS) Spanish.A translation done, following cross-cultural adaptation guidelines, which consisted forward translation, blind back an...

10.1590/0004-282x-anp-2020-0550 article EN cc-by Arquivos de Neuro-Psiquiatria 2021-12-17

Many studies attempting to assess the overall disease severity in different dementia syndromes have onlyincluded neuropsychological or functional measures. Examination of frequency and neuropsychiatric symptoms (NPS) not considered. NPS may be hallmark marked disability, caregiver distress severity. Objective: To evaluate correlation between NPSwith use Spanish versionthe Frontotemporal Lobar Degeneration- Clinical Dementia Rating (FTLD- CDR) Sum Boxes score Neuropsychiatric Inventory...

10.1016/j.jalz.2014.05.822 article EN Alzheimer s & Dementia 2014-07-01

The identification and validation of biomarkers for diagnosing, monitoring progression predicting onset AD has been a main focus research in the past 10 years. appropriate use criteria amyloid PET PiB (positron emission tomography with Aβ ligands) include patients persistent or progressive unexplained MCI, possible unclear clinical presentation dementia atypically early age onset. Amyloid imaging may be useful if differential diagnosis remains after FDG-PET. Our work analyze relevance about...

10.1016/j.jalz.2014.05.815 article EN Alzheimer s & Dementia 2014-07-01

The likelihood of progression from MCI to any form dementia has been suggested occur at a rate 3 5 times higher than those with normal cognition an annual 12-20%. patients negative AD biomarkers are supposed have lower risk related AD. However they still could suffer other non-AD etiologies and convert dementia. aim is assess the Mild Cognitive Impairment (MCI) PET PIB for Alzheimer's Disease (AD). Thirty-two diagnosed were selected. These underwent complete Neuropsychological battery; brain...

10.1016/j.jalz.2015.06.029 article EN Alzheimer s & Dementia 2015-07-01

Apathy is a predominant behavioral symptom in Alzheimer’s Disease with severe consequences every day function. Physicopathological aspects, clinical features, and differential diagnosis depression still remain controversial. The finding of biological markers apathy could be useful diagnostic tool, atrophy identification trough MRI represent this option. Our aim to study possible correlation between neuropsychiatric behavior focused localized cortical AD spectrum. 22 patients (dementia=8 mild...

10.1016/j.jalz.2016.06.1018 article EN Alzheimer s & Dementia 2016-07-01

The diagnosis of the syndrome called frontotemporal dementia complex involves distinction between three clinical subtypes: behavioral variant (FTDbv), semantic (SD) and nonfluent primary progressive aphasia (PNFA). CDR(clinical rating scale) is a tool designed to quantify severity symptoms also useful assess disease progression, particularly in due Alzheimer's disease. David Knopman cols developed new version scale by adding two extra domains (behavioral language) order detect progression...

10.1016/j.jalz.2013.04.149 article EN Alzheimer s & Dementia 2013-07-01

OBJECTIVE: To analyze shared mechanism of nicotine addiction and apathy by clinical assessment, magnetic resonance imaging (MRI) Difussion Tensor Imaging(DTI).

10.1212/wnl.80.7_supplement.p05.123 article EN Neurology 2013-02-12

Abstract Background Behavioral variant frontotemporal dementia (bvFTD) is a neurodegenerative disorder characterized by early and progressive changes in behavior, emotional processing executive control. This entity represents diagnostic challenge which positron emission tomography (PET) may play key role the diagnosis follow‐up vivo with minimally invasive method. The aim of this work to evaluate PET biomarkers cohort patients clinical bvFTD. Method 21 normal controls (NC: 64 ± 9 years) 20...

10.1002/alz.079225 article EN Alzheimer s & Dementia 2023-12-01
Coming Soon ...